Oral pharmacokinetics of omeprazole
- PMID: 6468483
- DOI: 10.1007/BF00543502
Oral pharmacokinetics of omeprazole
Abstract
The pharmacokinetics of omeprazole were studied in a group of healthy male subjects after single and repeated oral doses of 30 and 60 mg. Absorption of omeprazole from its enteric-coated formulation was unpredictable. There was a highly significant increase in the area under the plasma concentration time curve (AUC) after repeated dosing. Omeprazole increases its own relative availability following repeated dosing. This may be due to inhibition of gastric acid secretion by omeprazole which is an acid-labile compound.
Similar articles
-
Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.Drugs. 1986 Jul;32(1):15-47. doi: 10.2165/00003495-198632010-00002. Drugs. 1986. PMID: 3527658 Review.
-
Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure.Eur J Clin Pharmacol. 1985;28(6):637-40. doi: 10.1007/BF00607907. Eur J Clin Pharmacol. 1985. PMID: 4065187
-
Animal pharmacodynamics of omeprazole. A survey of its pharmacological properties in vivo.Scand J Gastroenterol Suppl. 1985;108:23-35. doi: 10.3109/00365528509095817. Scand J Gastroenterol Suppl. 1985. PMID: 3858975
-
Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man.Br J Clin Pharmacol. 1985 Aug;20(2):137-9. doi: 10.1111/j.1365-2125.1985.tb05044.x. Br J Clin Pharmacol. 1985. PMID: 3929808 Free PMC article.
-
[Inhibition of H+/K+-ATPase in the parietal cell with omeprazole: a new principle of gastric acid inhibition].Ned Tijdschr Geneeskd. 1985 Apr 13;129(15):679-82. Ned Tijdschr Geneeskd. 1985. PMID: 2986019 Review. Dutch. No abstract available.
Cited by
-
Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.Dig Dis Sci. 2007 Feb;52(2):390-5. doi: 10.1007/s10620-006-9490-9. Epub 2007 Jan 9. Dig Dis Sci. 2007. PMID: 17211705 Clinical Trial.
-
Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects.Eur J Clin Pharmacol. 1993;44(6):575-8. doi: 10.1007/BF02440862. Eur J Clin Pharmacol. 1993. PMID: 8405016 Clinical Trial.
-
Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.Drugs. 1986 Jul;32(1):15-47. doi: 10.2165/00003495-198632010-00002. Drugs. 1986. PMID: 3527658 Review.
-
Proton pump inhibitory therapy: then and now.Yale J Biol Med. 1996 Mar-Apr;69(2):175-86. Yale J Biol Med. 1996. PMID: 9112749 Free PMC article. Review.
-
Progress with proton pump inhibition.Yale J Biol Med. 1992 Nov-Dec;65(6):649-57;discussion 689-92. Yale J Biol Med. 1992. PMID: 1341069 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources